Overview: Protein Creatinine Ratio Panel
Introduction: The Protein Creatinine Ratio Panel is a diagnostic tool designed to assess proteinuria using urine samples. In India, proteinuria/microalbuminuria affects ~20-40 percent of diabetic/hypertensive patients (~100 million at risk), early marker of CKD progression to ESRD. High morbidity from under-testing in rural/low-SES patients with diabetes or hypertension, limited labs, delayed ACEi/ARB leading to rapid renal decline. Per nephrology practices aligned with ICMR, RSSDI, and Indian Society of Nephrology guidelines, the test employs spectrophotometry for protein, creatinine, and protein/creatinine ratio over 1-2 days with high accuracy, valuable as spot urine alternative to 24-hour collection (PCR >0.2 g/g abnormal). This diagnostic falls under renal screening and targets diabetic/hypertensive patients or those with edema, addressing accurate detection to guide renoprotective therapy and monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling convenient proteinuria assessment and reducing CKD burden. Its random urine-based approach ensures reliable ratio calculation.
Other Names: Protein Cr Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry/clinical pathology, compliant with 2025 standards.
Historical Milestone: Urine PCR standard since 2000s; in India, key in diabetes programs.
Purpose: The test assesses 3 parameters including protein to guide kidney damage screening, quantify proteinuria, inform therapy.
Test Parameters: 1. Protein, 2. Creatinine, 3. Protein/Creatinine Ratio.
Pretest Condition: No fasting required; patients should avoid heavy exercise.
Specimen: 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on diabetes, hypertension.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected proteinuria including ESRD, benefits of screening, and minimal discomfort from urine collection.
Procedural Considerations: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or infection can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: PCR >0.2 g/g indicates proteinuria; >3.5 g/g nephrotic range, necessitating specialist input.
Specialist Consultation: Nephrologists should be consulted for management.
Additional Supporting Tests: 24-hour urine protein, eGFR for confirmation.
Test Limitations: Transient elevations possible; comprehensive approach required.
References: Indian Journal of Nephrology 2024, CKD Studies India 2023.
